刚刚过去的2024年,港股医药生物市场中的106只个股,股价(后复权)累计实现上涨的有26只,占比约25%。 这里的医药生物市场,囊括了化学制药、中药、生物制品、医药商业、医疗器械、医疗服务这些细分市场。从涨幅最大或者跌幅最大的前十只个股来看,均以18A药企(港交所18A规则上市的公司)为主。 领涨公司背后 Choice金融端数据显示,2024年全年,领涨港股医药生物市场的是云顶新耀-B(...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.